Luckbox Leans in with Mark Cuban
By James Melton
Cost Plus Drugs Company is selling prescription medications at dramatically low prices
What would happen if drug pricing made sense to consumers?
Mark Cuban Cost Plus Drug Company, which launched its online pharmacy about a year ago, is trying to answer that question. Its approach is easy to understand—even if it’s difficult to implement.
First, CPD negotiates directly with manufacturers to get the best possible price. It adds a 15% markup based on the per-pill price that CPD pays to buy the medicines. Then, CPD adds a flat $3 pharmacy labor fee and $5 standard shipping to get to the total retail price.
Cuban believes strongly in CPD’s mission and business model. Among his many ventures, this is the first company to...
Topics
-
Why Q1 Earnings Season is So Important for the Regional Banks
|The continued slide in shares of New York Community Bancorp (NYCB) shows the regional banking crisis isn’t yet resolved -
Synopsys (SNPS)-ANSYS (ANSS) Merger: Two Key Partners of Nvidia Unite
|Nvidia announced at its annual GPU Technology Conference (GTC) that it is expanding its partnership with ANSYS (ANSS) -
Inevitable Evolution
By Ed McKinley
|Luckbox expects the march toward wider EV adoption will continue nearly unabated -
A Trump Reelection Could Shake Up the Energy Industry
|If Donald Trump is reelected for a second term in November, the energy sector could experience a shake up due to renewed support for traditional fossil fuel companies and a… -
Sugar Prices Expected to Build on Last Year’s Record Rally
|Sugar prices surged to 12-year highs in 2023 as poor growing conditions cut into global crop yields -
Robusta Coffee Beans Are Trading At Multi-Decade Highs
|Reduced supplies of coffee have contributed to higher prices, with the price of Robusta coffee beans recently climbing to multi-decade highs -
This is the Hottest Biotech ETF to Start 2024
|After two years of underperforming, the biotech sector appears to be rebounding with a strong performance in the Loncar Cancer Immunotherapy ETF (CNCR) -
Semiconductors, Crypto and Cannabis Lead the ETF Universe in Early 2024
|The stock market has outperformed so far in 2024, which has boosted the fortunes of many ETFs—particularly those levered to cannabis, cryptocurrencies, marine shipping and semiconductors -
4 of the Most Highly Anticipated IPOs in 2024
|The market for IPOs has been weak since the start of 2022, but there are several exciting companies expected to debut in 2024 -
The Recent Rally in Oil Prices Could Lift the Coal Sector
|Coal prices have been trending lower since September 2022, but the recent rally in crude oil prices could provide a boost to the coal sector -
Banking Crises and Black Swans Are Birds of the Same Feather
|On Jan. 31, New York Community Bancorp reported worse than expected Q4 earnings, triggering a selloff in the company’s shares and reigniting concerns over a broader regional banking crisis -
Predictions for 2024
|Our respect for the science of forecasting doesn’t prohibit us from engaging in the fun (and folly) of prediction. While we can’t promise outcomes, we can confirm our convictions, prepare… -
A Superforecaster Looks Ahead
By Ed McKinley
|Forecasting’s foreman offers a glimpse of the future and shares tips on making better predictions -
Can These Two Trading Strategies Really Predict a Stock’s Direction?
|Momentum and insider activity are anomalies that defy the efficient market hypothesis—a theory that says you can’t win big -
Existential Threats Aside, AI Will Be Good For Your Health
By James Melton
|Algorithms are already surprisingly good at diagnosing ailments, recommending treatment and predicting 10-year heart attack risk. But don’t get too excited. -
Factfulness Meets Superforecasting
By Ed McKinley
|Two movements aim to nudge society toward a more data-driven search for truth and probability -
Your Doctor, Only Smarter
By James Melton
|AI will help make physicians better at identifying red flags in your physical exam -
Is AI Exciting New Tech or an Existential Threat?
By Ed McKinley
|Experts and Superforecasters can’t reach consensus on humanity’s fate -
Macy’s: Rejected Takeover Provides New Opportunity for Options Sellers
|Macy’s recent takeover bid for $21/share makes the stock more attractive for options-focused opportunities